Tag Archives: inhibitor
Systemic therapy in juvenile localized scleroderma
Juvenile localized scleroderma, also known as morphea, is an rare condition, it occurs around 1 in 5000 children, where the skin and the tissues underneath the skin like fat tissue, muscle, tendons, and bone, get inflamed and
Molecular targeted therapy in alveolar soft part sarcoma
Alveolar soft part sarcoma is a malignant and rare tumor that includes about 1% of all STS (soft tissue sarcoma), and usually occurs in adolescents and young adults. This type of cancer has tendency toward distant metastasis
Potential biomarkers of CDK4/6 inhibitors in HR-positive advanced breast cancer
Thanks to the development of endocrine therapy, the mortality rate of estrogen receptor (ER)-positive breast cancer patients has been decreased drastically. In spite of the improvement, however, relapse and progression that are driven by different mechanisms are
A new strategy against cancer cells. Targeting the Rho-GTPases interactions: The case of the new compound 1A116
For the last decades scientist have been working hard to find cancer´s Achilles heel to design and develop more specific and efficacious therapeutic strategies for cancer. It has become clear that altered cell signaling is a key
A new drug to improve drug-eluting stents in coronary artery disease
Patients with symptomatic coronary artery disease often receive stent treatment in obstructed coronary arteries of the heart. Even though current generation drug-eluting stents perform very well in the short-term, concerns still exist about their long-term efficacy due
Activation by inhibition
Phosphorylation of proteins is one of the most important mechanisms through which protein function is quickly and reversibly regulated. Prototypically, an extracellular ligand binds to its cognate receptor(s) on the surface of a target cell, leading to
Chronic myeloid leukaemia: a success story in cancer therapy
Chronic myeloid leukaemia (CML) is a haematological malignancy caused by a chromosomal translocation that places the c-ABL oncogene, normally located on the long arm of chromosome 9, under the control of the breakpoint control region (BCR) on
Surrogate endpoints for overall survival in lung cancer patients treated with PD-1/PD-L1 blockade
Anti PD-1/PD-L1 antibodies are becoming key therapies in the treatment for advanced non-small-cell lung cancer (NSCLC). Surrogate endpoints for overall survival (OS) such as tumor response and progression-free survival (PFS) are useful to detect drug efficacy earlier,
A synthetic natural like product endowed with antiproliferative activity
The World Health Organization has reported that cancer is one of the major causes of morbidity and mortality affecting population in all countries and regions. The 2014 World Cancer Report of WHO indicated that in 2012 there
Kinase inhibitors and new treatments for asthma and COPD
Kinases are enzymes that phosphorylate proteins, leading to their activation within cells. Over 500 kinases have now been identified in human cells and they activate many processes in the cells, including the production of inflammatory mediators. Kinases
BRAF inhibitor and interferon alpha combination for melanoma treatment
In recent years approval has been granted to many therapeutic agents for the treatment of patients with metastatic melanoma. They include small molecule inhibitors, such as the selective inhibitors of the mutant BRAF (BRAF-I) or of MEK (MEK-I), and
